To include your compound in the COVID-19 Resource Center, submit it here.

Glactiv sitagliptin regulatory update

In May, Japan approved Glactiv sitagliptin to treat Type II diabetes in combination

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE